Phil Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport
{"title":"Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?","authors":"Phil Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport","doi":"10.1042/CS20240605","DOIUrl":null,"url":null,"abstract":"<p><p>Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.</p>","PeriodicalId":10475,"journal":{"name":"Clinical science","volume":"138 11","pages":"687-697"},"PeriodicalIF":6.7000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1042/CS20240605","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.
内皮素 A 和 B 受体以及钠-葡萄糖共转运体-2(SGLT-2)通道是改善内皮功能的重要靶点,近年来使用抑制剂进行干预已成为多项机理和临床结果试验的主题。显著的成功案例包括使用内皮素受体拮抗剂治疗肺动脉高压,以及使用 SGLT-2 抑制剂治疗心力衰竭和慢性肾病。在这篇综述中,我们将探讨以内皮功能障碍为核心的多种疾病的联合治疗逻辑。
期刊介绍:
Translating molecular bioscience and experimental research into medical insights, Clinical Science offers multi-disciplinary coverage and clinical perspectives to advance human health.
Its international Editorial Board is charged with selecting peer-reviewed original papers of the highest scientific merit covering the broad spectrum of biomedical specialities including, although not exclusively:
Cardiovascular system
Cerebrovascular system
Gastrointestinal tract and liver
Genomic medicine
Infection and immunity
Inflammation
Oncology
Metabolism
Endocrinology and nutrition
Nephrology
Circulation
Respiratory system
Vascular biology
Molecular pathology.